Surrozen Inc(SRZN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -44.28 | Insider Own | 48.17% | Shs Outstand | 11.8M | Perf Week | 19.87% |
| Market Cap | 0.36B | Forward P/E | - | EPS next Y | 48.52% | Insider Trans | -5.56% | Shs Float | 6.1M | Perf Month | -5.1% |
| Enterprise Value | 0.26B | PEG | - | EPS next Q | -1.1 | Inst Own | 70.94% | Short Float | 51.42% | Perf Quarter | 45.7% |
| Income | -0.35B | P/S | 30.99 | EPS this Y | 78.33% | Inst Trans | 2.76% | Short Ratio | 5.56 | Perf Half Y | -3.83% |
| Sales | 0.01B | P/B | - | EPS next 5Y | 51.7% | ROA | -320.9% | Short Interest | 3.13M | Perf YTD | 34.29% |
| Book/sh | -18.6 | P/C | 3.5 | EPS past 3/5Y | -27.67% 4.68% | ROE | - | 52W High | -19.77% ($37.83) | Perf Year | 121.03% |
| Cash/sh | 8.68 | P/FCF | - | Sales past 3/5Y | -34.72% - | ROIC | - | 52W Low | 166.46% ($11.39) | Perf 3Y | 416.16% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -195.46% | Gross Margin | 98.08% | Volatility(W/M) | 9.31% 10.29% | Perf 5Y | -70.59% |
| Dividend TTM | - | EV/Sales | 22.68 | Sales Y/Y TTM | -8.79% | Oper. Margin | -385.28% | ATR (14) | 2.59 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.14 | EPS Q/Q | -115.9% | Profit Margin | -3042.91% | RSI (14) | 62.28 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.14 | Sales Q/Q | 408.65% | SMA20 | 14.35% ($26.54) | Beta | 0.49 | Target Price | $48.4 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | 25.99% ($24.09) | Rel Volume | 0.25 | Prev Close | $29.53 |
| Employees | 44 | LT Debt/Eq | - | EPS/Sales Surpr. | 68.17% 969.98% | SMA200 | 21.35% ($25.01) | Avg Volume(3M) | 0.56M | Price | $30.35 |
| IPO | 2021/1/11 | Option/Short | Yes/Yes | Trades | 3028 | Volume | 142,702 | Change | 2.78% |
A US clinical-stage biotech company developing antibody-based tissue regeneration and repair therapeutics that selectively modulate the Wnt signaling pathway. Leveraging its expertise in Wnt biology, the company has recently sharpened its strategic focus on ophthalmology, continuing its drug development efforts centered on retinal disease treatment candidates.
Over the past 1 year, roughly in the middle
20% below its 1-year high.
Traded less than usual. That is 25% of its average volume.
SRZN has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +78.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,099. Peers typically go for $1,089.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -70.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
51.4% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #252 of 594 in the industry
Based on market cap of $357M.
FAQ
What kind of company is SRZN?
SRZN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SRZN?
The market cap of SRZN is approximately $357M, ranking 3,462 within its sector.
What is the 52-week high and low for SRZN?
SRZN has recorded a 52-week high of $37.83 and a low of $11.39.
